Pharmaceutical company influences on medication prescribing and their potential impact on quality use of medicines

Journal of Clinical Pharmacy and Therapeutics

Volumn 33, Issue 5, 2008, Pages 553-559

  Kyle, G J ^a   Nissen, L M ^a   Tett, S E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Influence; Medicine; Prescribing; Prescription sample; Qualitative modelling

Indexed keywords

ADVERTIZING; ARTICLE; CLINICAL PRACTICE; DRUG INDUSTRY; DRUG MARKETING; DRUG UTILIZATION; EVIDENCE BASED PRACTICE; PHYSICIAN ATTITUDE; PRESCRIPTION; THEORETICAL MODEL;

ADVERTISING AS TOPIC; DRUG INDUSTRY; EVIDENCE-BASED MEDICINE; HUMANS; MODELS, ORGANIZATIONAL; NEW ZEALAND; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PRESCRIPTION DRUGS; QUALITY OF HEALTH CARE; UNITED STATES;

EID: 52049089703     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00948.x     Document Type: Article

References (34)

1. IMS Health (2007) IMS Health reports global pharmaceutical market Grew 7.0 Percent in 2006, to $643 billion. [Report]. IMS Health; Available at: http://www.imshealth.com/ims/portal/front/articleC/0,2777,6319_3665_80560241, 00.html [cited 7 January 2007].
2. Oldani MJ (2004) Thick prescriptions: toward an interpretation of pharmaceutical sales practices. Medical Anthropology Quarterly, 18, 325 356.
3. Katz D, Caplan AL, Merz JF (2003) All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving. The American Journal of Bioethics, 3, 39 48.
4. Department of Health and Ageing (2000) National medicines policy. [Report]. Commonwealth of Australia; Available at: http://www.health.gov.au/ internet/main/publishing.nsf/Content/nmp-objectives-policy.htm/$FILE/ nmp2000.pdf [cited 7 January 2007].
5. Department of Health and Ageing (2002) The national strategy for quality use of medicines. [Report]. Commonwealth of Australia; Available at: http://www.health.gov.au/internet/main/publishing.nsf/Content/ CA777524C860DFF2CA256F1800468B61/$File/natstrateng.pdf [cited 7 January 2007].
6. Cutts C (2002) Identification of the influences on the quality use of medicines in general practice in rural Australia. PhD Thesis, University of Queensland, Brisbane, 266 p.
7. Wazana A (2000) Physicians and the pharmaceutical industry - is a gift ever just a gift? JAMA, 283, 373 380.
8. Steinman MA, Shlipak MG, McPhee SJ (2001) Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. American Journal of Medicine, 110, 551 557.
9. Randall ML, Rosenbaum JR, Rohrbaugh RM, Rosenheck RA (2005) Attitudes and behaviors of psychiatry residents toward pharmaceutical representatives before and after an educational intervention. Academic Psychiatry, 29, 33 39.
10. Rutledge P, Crookes D, McKinstry B, Maxwell SRJ (2003) Do doctors rely on pharmaceutical industry funding to attend conferences and do they perceive that this creates a bias in their drug selection? Results from a questionnaire survey. Pharmacoepidemiology and Drug Safety, 12, 663 667.
11. Blake RL, Early EK (1995) Patients' attitudes about gifts to physicians from pharmaceutical companies. Journal of the American Board of Family Practice, 8, 457 464.
12. Mintzes B (2006) Direct-to-consumer advertising of prescription drugs in Canada. What are the public health implications? [Report]. Toronto : Health Council of Canada.
13. Center for Drug Evaluation and Research. Guidance for Industry (1999) Consumer-directed broadcast advertisements [Report]. Food and Drug Administration; Available at: http://www.fda.gov/cder/guidance/1804fnl.pdf [cited 20 May 2008].
14. Angell M (2005) The truth about the drug companies. Carlton North, Vic, Canada : Scribe Publications.
15. Moynihan R, Cassels A (2005) Selling sickness: how drug companies are turning us all into patients. Crows Nest : Allen & Unwin.
16. Spiller LD, Wymer WW Jr. (2001) Physicians' perceptions and uses of commercial drug information sources: An examination of pharmaceutical marketing to physicians. Health Marketing Quarterly., 19, 91 106.
17. Weissman JS, Blumenthal D, Silk AJ et al. (2004) Physicians report on patient encounters involving direct-to-consumer advertising. Health Affairs, W219 W233 (web exclusive).
18. Cutts C, Tett SE (2005) Do rural consumers expect a prescription from their GP visit? Investigation of patients' expectations for a prescription and doctors' prescribing decisions in rural Australia. Australian Journal of Rural Health, 13, 43 50.
19. Gunnarsdottir AI, Kinnear M (2005) Factors that influence prescribers in their selection and use of COX-2 selective inhibitors as opposed to non-selective NSAIDs. Pharmacy World & Science, 27, 316 320.
20. Prosser H, Almond S, Walley T (2003) Influences on GPs' decision to prescribe new drugs - the importance of who says what. Family Practice, 20, 61 68.
21. Lenaghan E, Holland R, Brooks A (2007) Home-based medication review in a high risk elderly population in primary care - the POLYMED randomized controlled trial. Age and Ageing, 36, 292 297.
22. Lowe CJ, Raynor DK, Purvis J, Farrin A, Hudson J (2000) Effects of a medicine review and education programme for older people in general practice. British Journal of Clinical Pharmacology, 50, 172 175.
23. Naunton M, Peterson GM (2003) Evaluation of home-based follow-up of high-risk elderly patients discharged from hospital. Journal of Pharmacy Practice & Research, 33, 176 182.
24. Sorensen L, Stokes JA, Purdie DM, Woodward M, Elliott R, Roberts MS (2004) Medication reviews in the community: results of a randomized, controlled effectiveness trial. British Journal of Clinical Pharmacology, 58, 648 664.
25. Krska J, Cromarty JA, Arris F et al. (2001) Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. Age and Ageing, 30, 205 211.
26. Zermansky AG, Petty DR, Raynor DK, Freemantle N, Vail A, Lowe CJ (2001) Randomised controlled trial of clinical medication review by a pharmacist of elderly patients receiving repeat prescriptions in general practice. BMJ (Clinical Research Ed.), 323, 1340 1343.
27. The Royal Australasian College of Physicians (2006) Guidelines for ethical relationships between physicians and industry, 3rd edn. Sydney : The Royal Australasian College of Physicians.
28. Australian Medical Association (2002) Doctors' relationships with the pharmaceutical industry - 1994. Revised 2002 [Webpage]. Australian Medical Association Available at: http://www.ama.com.au/web.nsf/doc/WEEN-5GJ7MH [cited 20 May 2008].
29. Association of American Medical Colleges (2008) Industry Funding of Medical Education. Report of an AAMC Task Force [Report]. Association of American Medical Colleges; Available at: http://www.services.aamc.org/ Publications/showfile.cfm?file=version114.pdf&prd_id=232&prv_id= 281&pdf_id=114 [cited 20 May 2008].
30. Pharmaceutical Society of Australia (2008) Gifts from Pharmaceutical Companies [Webpage]. Pharmaceutical Society of Australia Available at: http://www.psa.org.au/site.php?id=630 [cited 20 May 2008].
31. American Medical Association (2002) Guidelines for Corporate Relationships [Webpage]. American Medical Association Available at: http://www.ama-assn.org/ama/pub/category/1904.html [cited 20 May 2008].
32. Canadian Pharmacists Association (1996) Guidelines on the Ethics of Relationships between Pharmacists and Pharmaceutical Manufacturers [Webpage]. Canadian Pharmacists Association Available at: http://www.pharmacists.ca/ content/about_cpha/who_we_are/policy_position/pdf/EthicsrelationshipsStatement- Final.pdf [cited 20 May 2008].
33. Coyle SL for the E, Human Rights Committee ACoP-ASoIM (2002) Physician-industry relations. Part 1: individual physicians. Annals of Internal Medicine, 136, 396 402.
34. Canadian Medical Association (1996) Guidelines for Physicians in Interactions with Industry [Webpage]. Canadian Medical Association Available at: http://www.policybase.cma.ca/dbtw-wpd/Policypdf/PD08-01.pdf [cited 20 May 2008].